title: Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.
abstract: Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.
authors.affiliation: Division of Rheumatology, Department of Medicine, Gülhane Military School of Medicine, Etlik/Ankara, 06018, Turkey. isimsek@gata.edu.tr
authors.forename: Ismail
authors.initials: I
authors.lastname: Simsek
authors.forename: Salih
authors.initials: S
authors.lastname: Pay
authors.forename: Ayhan
authors.initials: A
authors.lastname: Dinc
authors.forename: Hakan
authors.initials: H
authors.lastname: Erdem
authors.forename: Bulent
authors.initials: B
authors.lastname: Kurt
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D002276:Carcinoid Tumor / Q000139:chemically induced*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D047748:Pituitary ACTH Hypersecretion / Q000209:etiology; D018124:Receptors, Tumor Necrosis Factor; D025241:Spondylarthritis / Q000188:drug therapy; D013953:Thymus Neoplasms / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept